The multicenter, double-blinded, randomized, placebo-controlled phase 2 trial showed the benefits of a GLP-1 analog (liraglutide) [34] in patients with MASH. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.